Safety and efficacy of the therapeutic DNA-based vaccine VB10.16 in combination with atezolizumab in persistent, recurrent or metastatic HPV16-positive cervical cancer: a multicenter, single-arm phase 2a study

Safety and efficacy of the therapeutic DNA-based vaccine VB10.16 in combination with atezolizumab in persistent, recurrent or metastatic HPV16-positive cervical cancer: a multicenter, single-arm phase 2a study

Background Second-line treatment options for persistent, recurrent or metastatic (r/m) cervical cancer are limited. We investigated the safety, efficacy, and immunogenicity of the therapeutic DNA-based vaccine VB10.16 combined with the immune checkpoint inhibitor atezolizumab in patients with human...

Full description

Saved in:
Bibliographic Details
Main Authors: Hannelore Denys, Frederik Marmé, Frederic Forget, Lukas Rob, Pawel Blecharz, Kristina Lindemann, Peter Hillemanns, Linn Wölber, Theresa Link, Jean-Francois Baurain, Mariusz Bidziński, Linn Woelber, Michal ZikÁN, Josef Chovanec, Christian Dannecker, Stéphanie Henry, Hannelore G Denys, Velko Minchev, Anders Rosholm, Kaja C G Berg, Roberto S Oliveri, Marchela Koleva, Bozhil Robev
Format: Article
Language:English
Published: BMJ Publishing Group 2025-01-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/1/e010827.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/13/1/e010827.full

Similar Items